Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
17 studies found for:    mesothelioma AND South Carolina
Show Display Options
Rank Status Study
1 Completed Capecitabine in Treating Patients With Malignant Mesothelioma
Condition: Malignant Mesothelioma
Intervention: Drug: capecitabine
2 Active, not recruiting Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma
Conditions: Advanced Malignant Mesothelioma;   Epithelioid Mesothelioma;   Recurrent Malignant Mesothelioma;   Sarcomatoid Mesothelioma
Interventions: Drug: Cediranib Maleate;   Drug: Cisplatin;   Drug: Pemetrexed Disodium;   Other: Placebo
3 Completed S9810: Gemcitabine Plus Cisplatin in Treating Patients With Malignant Mesothelioma of the Pleura That Cannot Be Removed by Surgery
Condition: Malignant Mesothelioma
Intervention: Drug: gemcitabine hydrochloride
4 Completed
Has Results
Dasatinib in Treating Patients With Previously Treated Malignant Mesothelioma
Condition: Malignant Mesothelioma
Intervention: Drug: dasatinib
5 Recruiting Pemetrexed Disodium/Observation in Treating Patients W/ Malignant Pleural Mesothelioma w/Out Progressive Disease After 1st Line Chemotherapy
Condition: Malignant Mesothelioma
Interventions: Drug: pemetrexed disodium;   Other: clinical observation
6 Completed Gemcitabine and Epirubicin in Treating Patients With Malignant Mesothelioma
Condition: Malignant Mesothelioma
Interventions: Drug: epirubicin hydrochloride;   Drug: gemcitabine hydrochloride
7 Recruiting Nintedanib (BIBF 1120) in Mesothelioma
Condition: Mesothelioma
Interventions: Drug: Nintedanib;   Drug: Pemetrexed;   Drug: Cisplatin;   Drug: Placebo
8 Unknown  Collecting Tumor Samples From Patients With Gynecological Tumors
Condition: Cancer
Intervention: Other: biologic sample preservation procedure
9 Recruiting Phase Ib Study of Anetumab Ravtansine in Combination With Pemetrexed and Cisplatin in Mesothelin-expressing Solid Tumors
Condition: Medical Oncology
Interventions: Drug: BAY 94-9343;   Drug: Pemetrexed;   Drug: Cisplatin
10 Active, not recruiting LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE)
Condition: Tumors With CDK4/6 Pathway Activation
Intervention: Drug: LEE011
11 Recruiting Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated Fibroblast Growth Factor (FGF) Pathway Signaling
Condition: Cancer
Interventions: Drug: GSK3052230;   Drug: paclitaxel;   Drug: carboplatin;   Drug: docetaxel;   Drug: pemetrexed;   Drug: cisplatin
12 Completed PTK787/ZK 222584 in Treating Patients With Unresectable Malignant Mesothelioma
Condition: Malignant Mesothelioma
Intervention: Drug: PTK787/ZK 222584
13 Unknown  S0722: Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
Condition: Malignant Mesothelioma
Intervention: Drug: everolimus
14 Active, not recruiting Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma
Condition: Unresectable Pleural or Peritoneal Malignant Mesothelioma
Interventions: Drug: Tremelimumab;   Drug: Placebo
15 Recruiting Safety Study of MGD009 in B7-H3-expressing Tumors
Conditions: Mesothelioma;   Bladder Cancer;   Melanoma;   Squamous Cell Carcinoma of the Head and Neck;   Non Small Cell Lung Cancer;   Clear Cell Renal Cell Carcinoma;   Ovarian Cancer;   Thyroid Cancer;   Breast Cancer;   Pancreatic Cancer;   Prostate Cancer;   Colon Cancer;   Soft Tissue Sarcoma
Intervention: Biological: MGD009
16 Recruiting Phase II Anetumab Ravtansine as 2nd Line Treatment for Malignant Pleural Mesothelioma (MPM)
Condition: Mesothelioma
Interventions: Drug: Anetumab ravtansine (BAY 94-9343);   Drug: Vinorelbine
17 Recruiting A Phase I/IIa Study of BMS-986148 in Subjects With Select Advanced Solid Tumors
Condition: Advanced Cancer
Intervention: Drug: BMS-986148

Indicates status has not been verified in more than two years